基于3D Slicer软件计算的前列腺坏死率与前列腺动脉栓塞临床疗效的相关性研究及临床成功预测因素分析
本研究分析前列腺动脉栓塞(PAE)术后1个月前列腺坏死率与术后1年临床疗效的相关性,并探索临床成功的预测因素。151例PAE技术成功患者中,临床成功组126例、失败组25例;术后1个月坏死率与1年疗效评分比呈线性负相关(P<0.001),坏死率、初始前列腺体积和急性尿潴留是临床成功的独立预测因素,坏死率AUC为0.928。
要点
- PAE术后1个月前列腺坏死率与1年疗效评分比呈线性负相关(P<0.001)。
- 术后1个月坏死率预测临床成功的AUC为0.928,联合三项指标AUC为0.951。
- 初始前列腺体积较大、术后1个月坏死率较高及急性尿潴留是临床成功的独立预测因素。
核心结论
- PAE术后1个月前列腺坏死率越高,术后1年临床疗效可能越好,该坏死率有望成为PAE临床成功的预测因素。
研究设计与样本
- 回顾性分析151例PAE技术成功患者,将术后1个月前列腺MRI数据导入3D Slicer软件计算坏死率,分为临床成功组(n=126)和临床失败组(n=25),采用多因素logistic回归和ROC曲线评估预测因素。
关键影像表现/征象
- 术后1个月前列腺坏死率与术后1年疗效评分比呈线性负相关(P<0.001)。
- 临床成功组初始前列腺体积和术后1个月前列腺坏死率均显著高于临床失败组(P<0.001)。
- 急性尿潴留和腺瘤优势型BPH也与临床成功相关(P<0.05)。
诊断标准与关键数值
- 术后1个月前列腺坏死率预测临床成功的AUC为0.928。
- 初始前列腺体积预测临床成功的AUC为0.720。
- 急性尿潴留预测临床成功的AUC为0.599。
- 三项指标联合预测临床成功的AUC为0.951。
临床应用与阅片要点
- 可将PAE术后1个月MRI导入3D Slicer软件计算前列腺坏死率,用于预测术后1年临床疗效。
- 阅片时关注术后1个月前列腺坏死率,坏死率较高提示临床成功可能性较大。
- 初始前列腺体积较大、合并急性尿潴留的患者也提示临床成功可能性较高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To analyze the correlation between the prostate necrosis rate at 1-month after prostatic artery embolization (PAE) and the clinical efficacy at 1-year after PAE, and to explore potential predictors of clinical success after PAE for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH).
METHODS: The prostate magnetic resonance imaging data at 1-month after PAE were imported into 3D Slicer software for calculating the prostate necrosis rate and thus analyzing the relationship between the prostate necrosis rate at 1-month after PAE and the efficacy score ratio at 1-year after PAE. The 151 patients with PAE technical success were divided into a clinical success group (n = 126) and a clinical failure group (n = 25). Independent predictors of clinical success after PAE were analyzed by multifactorial logistic regression, and the predictive performance of each factor was evaluated by applying the receiver operating characteristic curve and the area under the curve (AUC).
RESULTS: There was a linear negative correlation between the prostate necrosis rate at 1-month after PAE and the efficacy score ratio at 1-year after surgery (P < 0.001). In the clinical success group, both the initial prostate volume (PV) and the prostate necrosis rate at 1-month after PAE were significantly higher than in the clinical failure group (P < 0.001), and acute urinary retention (AUR) and adenomatous-dominant BPH were also associated with clinical success (P < 0.05). Multifactorial logistic regression analysis revealed that larger initial PV, a higher prostate necrosis rate at 1-month after surgery, and AUR were independent predictors of clinical success after PAE. The AUC values for these three indicators and their combination were 0.720, 0.928, 0.599, and 0.951, respectively, in which the prostate necrosis rate at 1-month after PAE demonstrating a high predictive value.
CONCLUSION: The higher the prostate necrosis rate at 1-month after PAE, the better the clinical efficacy at 1-year after PAE is likely to be, and the prostate necrosis rate at 1-month after PAE is expected to become a predictor of clinical success after PAE.
引用
- Wang RL, Lin FF, Ruan DD, et al. A correlation study between prostate necrosis rate calculated by 3D Slicer software and clinical efficacy of prostatic artery embolization, along with an analysis of predictors of clinical success after prostatic artery embolization. Abdom Radiol (NY). 2023. PMID: 38158423. doi:10.1007/s00261-023-04131-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。